Blog
Apple Moves iPhone Production to India
October 18, 2022
Apple has moved its production to India for the first time - what are the commercial implications?
An interview with… An RPC Trainee
October 18, 2022
Alexandra Prato is a third-seat trainee at RPC and she's given us her insight into her experience at the firm, from why she chose RPC to the different tasks she's gotten involved with.
Things I Wish I Had Known Before Applying to Law Firms
October 17, 2022
What should you consider before beginning your law firm applications? We hear from an RPC trainee on her top tips for choosing a firm.
The UK’s Mini-Budget and ‘Trickle-Down Economics’
October 13, 2022
We take a look at the commercial takeaways you should be aware of from the chancellor's September 2022 mini-budget
5 Reasons To Apply for RPC’s Bristol Training Contract
October 7, 2022
Have you considered doing your training contract in Bristol? Trainee Thomas Challen gives us his top 5 reasons why it might be the perfect choice.
RPC’s Vacation Scheme: An Inside Look
October 6, 2022
Oluchi Nnadi (she/her) took part in RPC's Vacation Scheme in June of 2022, and she's given us an insider look into how she spent her two weeks at RPC, including some of her personal highlights, as well as what she has taken away from this experience.
Queen’s Counsel to King’s Counsel: A history
September 21, 2022
A look at what QC means, how it originated and how it has evolved throughout history.
SQE vs LPC: The Results Are Out
September 15, 2022
The first Solicitors Qualifying Examinations (SQE) took place in November 2021, with the results released in August. As the next round of the LPC-replacement gets underway, we take a closer look at the results published by the SRA.
Global Commitment to Russian Oil Sanctions Pays Off
September 2, 2022
It has now been reported that, for the first time since records began, Britain imported no Russian oil in June.
Pharmaceutical Giants at War: Moderna Sues Pfizer
September 2, 2022
Last week, American pharmaceutical company Moderna announced it was suing competitor Pfizer for patent infringement concerning the mRNA technology used in the COVID-19 vaccine.
Loading More Content